6’deoxyluciferin (luciferin h)

Need public description.

Compound information managed by NaPDI


None listed

None listed

None listed

ID Subject of Study Study Name Name Type Overall Effect Enzymes Transporters Object Object Metabolite Precipitant
NPDI-m-NOOw Kratom (Mitragyna speciosa) Inhibitory effect of mitragynine on human cytochrome P450 enzyme activities Enzyme kinetics of CYP2C9 In Vitro Enzyme Kinetics positive — In Vitro Detectable Kinetic Metabolism
  • CYP2C9
6’deoxyluciferin (luciferin h) luciferin
NPDI-v2Z25g Kratom (Mitragyna speciosa) Inhibitory effect of mitragynine on human cytochrome P450 enzyme activities POS. CONTROL: Inhibition of CYP2C9 by sulfaphenazole In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP2C9
6’deoxyluciferin (luciferin h) luciferin sulfaphenazole
NPDI-1tFkCA Kratom (Mitragyna speciosa) Inhibitory effect of mitragynine on human cytochrome P450 enzyme activities Inhibition of CYP2C9 by mitragynine In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP2C9
6’deoxyluciferin (luciferin h) luciferin mitragynine
NPDI-H6ZqbA Kratom (Mitragyna speciosa) Evaluation of selected Malaysian medicinal plants on phase I drug metabolizing enzymes, CYP2C9, CYP2D6 and CYP3A4 activities in vitro POS. CONTROL: Inhibition of CYP2C9 by sulfaphenazole In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP2C9
6’deoxyluciferin (luciferin h) luciferin sulfaphenazole
NPDI-jkwBEg Kratom (Mitragyna speciosa) Evaluation of selected Malaysian medicinal plants on phase I drug metabolizing enzymes, CYP2C9, CYP2D6 and CYP3A4 activities in vitro Inhibition of CYP2C9 by M. speciosa methanolic extract In Vitro Enzyme Inhibition negative — In Vitro Enzyme Negligible Inhibition
  • CYP2C9
6’deoxyluciferin (luciferin h) luciferin methanolic extract of kratom